Biotech Alpha

One stop resource for biotech catalysts, insight and reaction.

[Biotech Alpha @BiotechAlpha]

Feuerstein's $CRBP bear makes another appearance. Still anonymous. No surprise now he/she proven wrong.

[Biotech Alpha @BiotechAlpha]

$CRBP brave to go after CRISS but it paid off. Excellent data. Very much one to watch going forward.

[Biotech Alpha @BiotechAlpha]

$CARA is one of the best discount entries available right now. Multiple near term catalysts, would make a great buy/partner for a big name.

[Biotech Alpha @BiotechAlpha]

Markets surprised $AVXS doesn't need a control arm? No chance the FDA was going to request one. Giving babies SMA placebo is death sentence.

[Biotech Alpha @BiotechAlpha]

$PTN data is spot on. Ignore misinformed sggstns of endpoint switching. This is a new landscape. HSDD framework unavailable at trial start.

[Biotech Alpha @BiotechAlpha]

$NVO out of oral insulin. Road now clear for $ORMP. Perhaps Novo mgmt are worried or-ins works and could derail its entire insulin program?

[Biotech Alpha @BiotechAlpha]

$GALE RS. These things are sometimes necessary. Phase III needs funding. OTC would make it tough to raise. All eyes now on 401 protocol.

[Biotech Alpha @BiotechAlpha]

$CPRX SPA now parallel, not crossover. Stat sig JUST reached in 1st co-primary for 1st phase 3. Design shift removes some confidence in SPA.

[Biotech Alpha @BiotechAlpha]

$OPHT Fovista pricing is going to be key. P=0.019 at 62% add benefit from b.line sounds great. "An extra 4 letters" takes the shine off.

[Biotech Alpha @BiotechAlpha]

$PTI down 33%, great entry OPP. Delays rooted in healthy volunteer murder and screening halt at 3 sites for H. Matthew. Blind sell off.

[Biotech Alpha @BiotechAlpha]

That said, $IMNP early data strong. Big market, relatively untapped (definitely under-served). Loading up on way down might be a nice play.

[Biotech Alpha @BiotechAlpha]

Good news $IMNP. 40% gains unwarranted. Protocol needs revision. 6 mnths+ before action. Cheaper shares will be av before pivotal kicks off.

[Biotech Alpha @BiotechAlpha]

$AEZS 25% off Oct high. Catalysts: 2X phase 3 topline this quarter. 2X NDAs with the FDA 1Q17. RDO dilutive but needed for final dev hurdle.

[Biotech Alpha @BiotechAlpha]

OncoGenex $OGXI data misleading. Never trust a one sided p-value. Even with benf of doubt, result is non stat-sig. 50% gains VERY generous.

[Biotech Alpha @BiotechAlpha]

Myovant $MYOV IPO tomorrow. Same parent company/ownership structure as Axovant $AXON. AXON biggest biotech IPO ever. Now worth $1.3bn.

[Biotech Alpha @BiotechAlpha]

Feuerstein: "The data... show no impact on... fibrosis at the doses currently being tested in phase II"
https://t.co/6gORGSiFH6
Slide 16

[Biotech Alpha @BiotechAlpha]

Feuerstein's $CRBP thesis is full of holes. Resunab is peripheral not CNS, pain mgmt comparison is moot. Poor CNS availability actually +ve.

[Biotech Alpha @BiotechAlpha]

Propanc $PPCH running on a preclin toxicokinetic completion. Not game changing, but another box ticked as the clinic beckons. One to watch.

[Biotech Alpha @BiotechAlpha]

Dipexium $DPRX CEO on Locilex:

Statement: "Considering potential regulatory pathways forward."
Translation: "Back to the drawing board."

[Biotech Alpha @BiotechAlpha]

Sticking with $ADRO, Port/Systemic differentiation is so important here. Of course, in rush to publish first, pop media fails to mention it.